Tomo Radiation

MADISON, Wis. - (Marketwire - November 24, 2009) - TomoTherapy Incorporated (NASDAQ: TOMO) announced today that a research study published in the November 11, 2009 International Journal of Radiation Oncology * Biology * Physics - commonly known as Red Cross Journal - noted that TomoTherapy (SM) processing time could be reduced by up to 66 percent by using advanced techniques of radiotherapy. In addition, these techniques have improved the quality plan also minimizes the amount of radiation received by normal tissues.

The study, entitled "Dynamic Jaws Couch dynamic spiral TomoTherapy," was led by Dr. Florian Sterzing, Department of Radiation Oncology at the University of Heidelberg Clinic to explore the benefits of advanced technology TomoTherapy delivery . This method of delivery would be based on a dynamic collimator that can automatically adjust the size of the radiation beam to maximize dose to the target and spare the surrounding healthy tissue. Another key element would be a patient couch that can be designed to accelerate the processing time by the rapid movement between target tumors or in areas which do not require high doses of radiation. University Hospital Heidelberg study concluded that the combination of these two advances in research, they were able to develop treatment plans that indicates the processing time significantly reduced and quality improved treatment planning.

"Our experience in treating patients with TomoTherapy leads us to believe that the techniques we explored in our research could lead to more accurate and faster treatment," said Dr. Sterzing. "Although our study was limited to applications of nasopharyngeal cancer, we believe that these techniques would also be valuable in the treatment of cancers throughout the body, especially cancers of the prostate and those involving multiple metastases."

New treatment system TomoHD a„c technology equipped for Advanced Delivery
"At the annual meeting of the American Society for Radiation Oncology (ASTRO) earlier this month, we began processing system TomoHD and demonstrated how advanced TomoTherapy delivery technique could be used in conjunction with this new processing system, "said Fred Robertson, MD, President and CEO of TomoTherapy." We believe the combination of multi-purpose platform with the delivery of advanced technology in the clinical study at the University of Heidelberg to allow TomoTherapy continue to advance patient care. These innovations will enhance our unique form of beam delivery, already widely considered the gold standard. "

TomoHD treatment system will be commercially available in the second half of 2010 and was designed to support advanced TomoTherapy delivery technology. The advanced TomoTherapy delivery technique is currently a work in progress and not available for sale.

University Clinic Heidelberg is a research partner of TomoTherapy Incorporated. TomoTherapy Representatives are co-authors of the study above.

About TomoTherapy Incorporated
TomoTherapy Incorporated develops, markets and sells advanced radiotherapy solutions that can be used to treat a wide variety of cancers, the most common complex. The ring gantry-based TomoTherapy ® platform combines integrated CT imaging with conformal radiation therapy to deliver sophisticated radiation treatments with speed and precision while reducing radiation exposure to surrounding healthy tissue. TomoTherapy Suite solutions include its flagship product, Hi · Art ® treatment system, which has been used to provide over three million CT-guided radiation therapy helical intensity modulated (IMRT) treatment fractions, the system TomoHD treatment a„c, designed to allow ca.